StemCell Therapy

The sun strikes every square meter of our planet with more than 1,360 watts of power. Half of that energy is absorbed by the atmosphere or reflected back into space. 700 watts of power, on average, reaches Earth’s surface. Summed across the half of the Earth that the sun is shining on, that is 89 petawatts of power. By comparison, all of human civilization uses around 15 terrawatts of power, or one six-thousandth as much. In 14 and a half seconds, the sun provides as much energy to Earth as humanity uses in a day.

The numbers are staggering and surprising. In 88 minutes, the sun provides 470 exajoules of energy, as much energy as humanity consumes in a year. In 112 hours – less than five days – it provides 36 zettajoules of energy – as much energy as is contained in all proven reserves of oil, coal, and natural gas on this planet.

[More]

U.S. Supreme Court, ruling allows shareholders to sue Pharma and biotechnology companies for failing to report adverse drug events/ dangerous side effects.

Maker of homeopathic remedies Matrixx Initiatives, was sued by investors once it came to know their marketed nasal spray linked to a string of instances in which people using the treatment lost their sense of smell. The adverse events were reported back to the company by several medical professionals and patients, but never amounted to a statistically significant group. Matrixx argued it wasn’t responsible for reporting scattered and unreliable anecdotal evidence of adverse events. But the supremed court said No

http://www.bloomberg.com/news/2011-03-22/drugmaker-investor-lawsuits-backed-by-u-s-supreme-court-4-.html

Compare that to the Indian Law System

Madras High Court in India allowed a stay on immediate withdrawal of drugs banned  due to Severe Side Effects. The  pediatric doses of pain reliever nimesulide and anti-cold medicine phenylpropanolamine banned in  market due to harmful side effects, Indian Drugs Manufacturers Association & Confederation of Indian Pharmaceutical Industries put revenue loss to industry above safety of patients & managed to get a reversal of the ban.

http://www.business-standard.com/india/news/hc-stayimmediate-withdrawalbanned-drugs/429458/

Opposite to good carbohydrate (= "Slow Carbs”), bad carbohydrates – in neo-German also known as “Fast Carbs“ – cause the blood sugar level to rise quickly.
The faster – and thus the higher concentrated – carbohydrates are, the more insulin our body will produce in order to lower the blood sugar level.

As a consequence thereof, the blood sugar level will drop below normal, the appetite – in particular for sweets – will increase, and fat burning will be restricted during this «insulin fattening».

Therefore, GI and GL were invented, to facilitate distinction between «bad» and «good» carbohydrates.

Glycemic Index (GI)
The glycemic index – in short GI – is exclusively applied to foods containing carbohydrates. The GI does not rate foodstuffs with respect to their carbohydrate content but provides figures on their respective blood sugar level increasing effects. Read more...

Immunice for Immune Support

The sun strikes every square meter of our planet with more than 1,360 watts of power. Half of that energy is absorbed by the atmosphere or reflected back into space. 700 watts of power, on average, reaches Earth’s surface. Summed across the half of the Earth that the sun is shining on, that is 89 petawatts of power. By comparison, all of human civilization uses around 15 terrawatts of power, or one six-thousandth as much. In 14 and a half seconds, the sun provides as much energy to Earth as humanity uses in a day.

The numbers are staggering and surprising. In 88 minutes, the sun provides 470 exajoules of energy, as much energy as humanity consumes in a year. In 112 hours – less than five days – it provides 36 zettajoules of energy – as much energy as is contained in all proven reserves of oil, coal, and natural gas on this planet.

[More]

U.S. Supreme Court, ruling allows shareholders to sue Pharma and biotechnology companies for failing to report adverse drug events/ dangerous side effects.

Maker of homeopathic remedies Matrixx Initiatives, was sued by investors once it came to know their marketed nasal spray linked to a string of instances in which people using the treatment lost their sense of smell. The adverse events were reported back to the company by several medical professionals and patients, but never amounted to a statistically significant group. Matrixx argued it wasn’t responsible for reporting scattered and unreliable anecdotal evidence of adverse events. But the supremed court said No

http://www.bloomberg.com/news/2011-03-22/drugmaker-investor-lawsuits-backed-by-u-s-supreme-court-4-.html

Compare that to the Indian Law System

Madras High Court in India allowed a stay on immediate withdrawal of drugs banned  due to Severe Side Effects. The  pediatric doses of pain reliever nimesulide and anti-cold medicine phenylpropanolamine banned in  market due to harmful side effects, Indian Drugs Manufacturers Association & Confederation of Indian Pharmaceutical Industries put revenue loss to industry above safety of patients & managed to get a reversal of the ban.

http://www.business-standard.com/india/news/hc-stayimmediate-withdrawalbanned-drugs/429458/

Joel Fuhrman, M.D.

The leading cause of death for male gorillas in zoos is heart disease. Sadly, animals that live in close contact with (and fed by) humans end up with human chronic diseases.
Gorillas are the largest of the primates, and they are one of the four species of great apes (great apes make up the Hominidae superfamily, which includes chimpanzees, bonobos, orangutans, and gorillas). Following chimpanzees, gorillas are the closest living relatives to humans, differing in only about 3% of our genetic makeup.
Gorillas are herbivores that live in the forests of central Africa, where they can eat up to 50 pounds of vegetation each day, mostly leaves and fruit. Although most gorillas have a preference for fruit, they also eat large amounts of leaves, plus herbs and bamboo, and occasionally insects. In the wild, gorillas spend most of their day foraging and eating.1
In the wild, gorillas eat an extremely high fiber diet, and derive a significant proportion of caloric energy from the fermentation of fiber by bacteria in the colon, producing short-chain fatty acids. The approximate proportions of macronutrients in a wild gorilla’s diet is 2.5% of calories from fat, 24.3% from protein, 15.8% (non-fiber) carbohydrate, and up to 57.3% from short chain fatty acids derived from bacterial fermentation of fiber.2
In contrast, the standard diet for gorillas in captivity is usually not made up of natural leaves, herbs, and fruits – it is a diet of nutrient-fortified, high-sugar, high-starch processed food. Read more...

Immunice for Immune Support

Deana Ferreri, Ph.D.

It is becoming more widely known that obesity can lead to a premature death – but what about those who fall in between healthy weight and obese? A new study suggests that even “a few extra pounds” can be dangerous.

This comes just a few months after a large study that concluded that waist circumference was associated with risk of death from all causes. These two studies used different methods of measurement, but they agree on a very important point – even a small amount of excess weight increases the risk of death. In the waist circumference study, even people who had a normal body mass index (BMI; calculated based on height and weight) were at greater risk of death if they had a 4-inch larger waist compared to others in their BMI category – that four extra inches of abdominal fat translated into a 16% (men) and 25% (women) increase in mortality risk over a nine year period. Read more...

Ayurtox for Body Detoxification

Deana Ferreri, Ph.D.

It is becoming more widely known that obesity can lead to a premature death – but what about those who fall in between healthy weight and obese? A new study suggests that even “a few extra pounds” can be dangerous.

This comes just a few months after a large study that concluded that waist circumference was associated with risk of death from all causes. These two studies used different methods of measurement, but they agree on a very important point – even a small amount of excess weight increases the risk of death. In the waist circumference study, even people who had a normal body mass index (BMI; calculated based on height and weight) were at greater risk of death if they had a 4-inch larger waist compared to others in their BMI category – that four extra inches of abdominal fat translated into a 16% (men) and 25% (women) increase in mortality risk over a nine year period. Read more...

Ayurtox for Body Detoxification

A recent ABC News investigation has identified a connection between the use of the popular denture cream Fixodent and permanent neurological disorders. Some Fixodent users allege that regular use of the cream has caused them to develop serious, debilitating nerve damage, which has sparked a class-action lawsuit against Proctor and Gamble (P&G), the maker of Fixodent.

"I started getting tingling in my fingertips," said Mark Jacoby, a Fixodent victim, to ABC News' 20/20 anchor Chris Cuomo. "I started getting weaker and, you know, I couldn't walk right, off balance and I'm at this point now."

The Fixodent ingredient in question is zinc, which unless taken along with copper, can rob the body of the necessary mineral over time and cause irreversible nerve damage. And since denture users affix zinc-containing creams to their gums every single day, their long-term absorption rates of zinc are much higher than normal than an average person's. Read more...

Ayurtox for Body Detoxification

A new survey of 500+ clinical research site professionals outlines the  impact of complex, clinical trials in clinical trial sites. The survey focused on 3-year trial trends and found key challenges in subject recruitment/retention and tracking and reporting data. Increased complexity also impacted trial financials– especially negotiating contracts and managing profitability.

The December, 2010 survey was conducted among investigators, study coordinators and other clinical site professionals from large organizations, such as Mayo Clinic and Johns Hopkins, hospitals like Rush Presbyterian and the Hospital for Sick Children, as well as multi-specialty and private practices. Clinical Research Site Training (CRST), conducted the survey.

Analysis of the survey findings shows that

• 66% of large organizations report an increase in trials conducted
• 60% of trial sites report increasing difficulty in managing trial profitability
• 40% report increasing difficulty in recruiting and retaining subjects
• Training remains a major issue, even though over 50% report an increase in training
• 80%+ of nurses want more QA training
• 60%+ of all respondents want more FDA Audits training

The survey also explored sites’ Web use for work information. In spite of increased specialized Web content about the clinical research site “world”, awareness and usage were both relatively low.

• Google (or other search sites) was the primary information tool
• Only the NIH and Clinical Trial Network sites have over 50% awareness among all site professionals
• Usage of major specialized sites averaged less than 40% for nurses and less than 20% for doctors

CRST suggest that clinical research sites should:

• Increase training on financial management, site QA, subject recruitment/retention and FDA inspections;
• Manage the convergence of increased and more complex trials by improving both new staff recruitment and experienced staff retention;
• Reach out on the Web for new/improved ways of working from both formal information sites and clinical research site communities.”

Full results of the survey are available on the CRST website http://www.crstnet.com

Contacts

CRST
Lester Levine, 484-798-7503
President
Fax: 215-477-2522
lester.levine@crstnet.com

Dr. Pauline Chen in the NY Times reports that “When Patients Share Their Stories, Health May Improve”. HC Catalyst uses the same methodology to increase patient adherence to prescription medicines.

hcCatalyst Adherence Driver uses patients to motivate other patients to stay adherent. And, we do this without remunerating, scripting or training. It’s genuine and without the liability issues associated with paid or trained spokespersons.

Details on http://www.hccatalyst.com/solutions.html

OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

CONTACTS

International Stem Cell Corporation

Kenneth C. Aldrich, Executive Chairman

1-760-940-6383

kaldrich@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.

ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.

Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Simon Craw, PhD, Vice President
760-940-6383
sc@intlstemcell.com

A recent ABC News investigation has identified a connection between the use of the popular denture cream Fixodent and permanent neurological disorders. Some Fixodent users allege that regular use of the cream has caused them to develop serious, debilitating nerve damage, which has sparked a class-action lawsuit against Proctor and Gamble (P&G), the maker of Fixodent.

"I started getting tingling in my fingertips," said Mark Jacoby, a Fixodent victim, to ABC News' 20/20 anchor Chris Cuomo. "I started getting weaker and, you know, I couldn't walk right, off balance and I'm at this point now."

The Fixodent ingredient in question is zinc, which unless taken along with copper, can rob the body of the necessary mineral over time and cause irreversible nerve damage. And since denture users affix zinc-containing creams to their gums every single day, their long-term absorption rates of zinc are much higher than normal than an average person's. Read more...

Ayurtox for Body Detoxification

A new survey of 500+ clinical research site professionals outlines the  impact of complex, clinical trials in clinical trial sites. The survey focused on 3-year trial trends and found key challenges in subject recruitment/retention and tracking and reporting data. Increased complexity also impacted trial financials– especially negotiating contracts and managing profitability.

The December, 2010 survey was conducted among investigators, study coordinators and other clinical site professionals from large organizations, such as Mayo Clinic and Johns Hopkins, hospitals like Rush Presbyterian and the Hospital for Sick Children, as well as multi-specialty and private practices. Clinical Research Site Training (CRST), conducted the survey.

Analysis of the survey findings shows that

• 66% of large organizations report an increase in trials conducted
• 60% of trial sites report increasing difficulty in managing trial profitability
• 40% report increasing difficulty in recruiting and retaining subjects
• Training remains a major issue, even though over 50% report an increase in training
• 80%+ of nurses want more QA training
• 60%+ of all respondents want more FDA Audits training

The survey also explored sites’ Web use for work information. In spite of increased specialized Web content about the clinical research site “world”, awareness and usage were both relatively low.

• Google (or other search sites) was the primary information tool
• Only the NIH and Clinical Trial Network sites have over 50% awareness among all site professionals
• Usage of major specialized sites averaged less than 40% for nurses and less than 20% for doctors

CRST suggest that clinical research sites should:

• Increase training on financial management, site QA, subject recruitment/retention and FDA inspections;
• Manage the convergence of increased and more complex trials by improving both new staff recruitment and experienced staff retention;
• Reach out on the Web for new/improved ways of working from both formal information sites and clinical research site communities.”

Full results of the survey are available on the CRST website http://www.crstnet.com

Contacts

CRST
Lester Levine, 484-798-7503
President
Fax: 215-477-2522
lester.levine@crstnet.com

Dr. Pauline Chen in the NY Times reports that “When Patients Share Their Stories, Health May Improve”. HC Catalyst uses the same methodology to increase patient adherence to prescription medicines.

hcCatalyst Adherence Driver uses patients to motivate other patients to stay adherent. And, we do this without remunerating, scripting or training. It’s genuine and without the liability issues associated with paid or trained spokespersons.

Details on http://www.hccatalyst.com/solutions.html

OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

CONTACTS

International Stem Cell Corporation

Kenneth C. Aldrich, Executive Chairman

1-760-940-6383

kaldrich@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.

ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.

Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Simon Craw, PhD, Vice President
760-940-6383
sc@intlstemcell.com